Dianthus Therapeutics Inc DNTH
$111.10 $1.59 (1.45%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
DNTH Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Dianthus Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Dianthus Therapeutics Inc. Stock Analysis DNTH
United States Health Care Mid Cap Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Dianthus Therapeutics Inc (DNTH) Chart
Financial Metrics & Statements of Dianthus Therapeutics Inc (DNTH)
FAQ's for Dianthus Therapeutics Inc (DNTH)
- As of August 2026, Dianthus Therapeutics Inc DNTH is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Dianthus Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Dianthus Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Dianthus Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Dianthus Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Dianthus Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Dianthus Therapeutics Inc (DNTH)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
